MNTA JNJ Bayer etc: I think the FDA will likely approve Xarelto for VTE prevention because the bleeding risk in this indication is not bad relative to the efficacy. This is consistent with what one would expect to see from an FXa inhibitor with no activity against FIIa.
However, approval in VTE prevention will not make Xarelto a bona fide competitor in ACS; for that to happen, the phase-3 trial cited in #msg-39151366 will have to succeed. Regards, Dew
Market Data 
Markets 
AI
